Advisory
Committee for Pharmaceutical Science Meeting
Bioequivalence of Topical Products
Questions for the Committee:
DPK
What type of studies should be conducted to validate the DPK
method?
Q3
What type of data is needed to demonstrate that two products
are Q3 equivalent?
How should the Q3 concept be validated or demonstrated?
· Demonstration
that we can detect changes in manufacturing processes?
· Demonstration
that we can detect formulations with known differences?
· Demonstration
that drug release rates are identical?
Bioequivalence for topical products
What role should Q3 and DPK play in the demonstration of
bioequivalence for topical products?
· Under what
circumstances should Q3 equivalence be sufficient to justify a wavier of in
vivo bioequivalence tests?
· Under what
circumstances should Q3 equivalence and a DPK method in healthy subjects be
sufficient to determine bioequivalence?
Nomenclature
Questions for the Committee:
1. How can the Agency best implement new
nomenclature or change existing nomenclature to comply with newer standards?
2. Is it reasonable or useful to include a
quantifiable attribute when defining a dosage form or distinguishing between
closely related dosage forms where appropriate?
Can such an approach be viewed as too arbitrary in some cases and too
rigid in other cases?
3. Has the update on topical dosage forms
presented today addressed the questions/comments raised by the ACPS at the
March 2003 meeting?
4. Is the proposed criterion, i.e., USP
disintegration time of less than one minute, reasonable for defining an orally
disintegrating tablet?